Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dna X (SONM) Equity Average (2018 - 2025)

Dna X filings provide 8 years of Equity Average readings, the most recent being -$4.3 million for Q4 2025.

  • On a quarterly basis, Equity Average fell 189.71% to -$4.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$4.3 million, a 189.71% decrease, with the full-year FY2025 number at -$6.8 million, down 181.92% from a year prior.
  • Equity Average hit -$4.3 million in Q4 2025 for Dna X, down from -$1.0 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $23.9 million in Q1 2021 to a low of -$4.3 million in Q4 2025.
  • Median Equity Average over the past 5 years was $15.9 million (2021), compared with a mean of $13.2 million.
  • Biggest five-year swings in Equity Average: surged 134.79% in 2023 and later crashed 189.71% in 2025.
  • Dna X's Equity Average stood at $15.6 million in 2021, then surged by 30.19% to $20.4 million in 2022, then increased by 11.7% to $22.7 million in 2023, then plummeted by 78.78% to $4.8 million in 2024, then tumbled by 189.71% to -$4.3 million in 2025.
  • The last three reported values for Equity Average were -$4.3 million (Q4 2025), -$1.0 million (Q3 2025), and -$1.2 million (Q2 2025) per Business Quant data.